RCRossana Cunha

Rossana Cunha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rossana Cunha has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enfermeiros na pesquisa clínica

    by Sheila Lima, Milca Valmérica Castro de Oliveira Mesquita, Rossana Cunha, Maria Irenice Santos de Santana, Maria das Graças Washington Casimiro Carreteiro, Jeane da Silva Rocha Santos, Carolina de Araújo Medeiros, Betânia da Mata Ribeiro Gomes

    Este estudo descreve a atuação de enfermeiras na pesquisa clínica de uma instituição pública, à luz da teoria do reconhecimento de Axel Honneth. Trata-se de um relato de experiência elaborado no contexto da prática diária das enfermeiras autoras, que atuam na pesquisa clínica de um hospital universitário de alta complexidade, especializado e referência em doenças cardiovasculares, do Norte/Nordeste, localizado no município do Recife/PE, Brasil. O período de observação ocorreu de agosto de 2019 a agosto de 2020. O estudo permitiu reconhecer a teoria do reconhecimento como uma realidade social vivenciada pelos participantes de estudos clínicos, impondo a busca de suas identidades reconhecidas pela aceitação nas relações com o próximo, na prática institucional e na convivência em comunidade. Concluindo que a vivência do enfermeiro como responsável pelo acolhimento dos participantes, seja no recrutamento ou nas etapas de seguimento do estudo, permite praticar a teoria do reconhecimento de Axel Honneth ao considerar a individualidade e o nível de compreensão dos participantes, esclarecendo seu papel, sua autonomia e sua importância no contexto dos avanços da saúde, dirimindo possibilidades de conflitos de interesse.

  • Open Access

    The trajectories of CD4 T lymphocytes over time in patients who have defaulted on treatment for tuberculosis in a cohort of people living with HIV, Recife/PE

    by Rossana Cunha, Demócrito de B. M. Filho, Maria de Fátima P. M. Albuquerque, Heloísa R. Lacerda, George T. N. Diniz, Ulisses R. Montarroyos, Laura C. Rodrigues, Líbia Cristina R. Vilela Moura, Ricardo A. A. Ximenes

    Background: The CD4 T lymphocyte count in people living with HIV (PLHIV) is a predictor for the progression of the disease (AIDS), survival and response to antiretroviral treatment (ART). A CD4 T lymphocyte count of less than 200 cells/mm3 is indicative of a greater risk for the onset of opportunistic diseases and death. Defaulting on treatment for tuberculosis (TB) may impact immune recovery in PLHIV who are taking ART. The aim of this study was to investigate an association of the CD4 lymphocyte with TB treatment Trajectory and with death. Methods: A cohort of PLHIV over eighteen years of age and who were taking ART and who had defaulted on pulmonary TB treatment. Latent Class analysis was used to identify different trajectories of CD4 T lymphocyte counts over time. Results: Latent class 1 (High CD4 trajectory) grouped individuals together who were characterized as maintaining a low probability (0 to 29%) of a CD4 count ≤ 200 cells/mm3over time, while latent class 2 (Low CD4 trajectory) grouped individuals together with a high probability (93% to 60%), and latent class 3 (Fluctuating CD4 trajectory), grouped individuals with a fluctuating probability (66% to 0%). The chance of defaulting on treatment earlier (≤ 90 days) was four times higher in latent class 2 (Low CD4 trajectory). Although there was no statistical significance, there was a higher frequency of deaths in this same latent class. Conclusion: Individuals with a high probability of a CD4 count ≤ 200 cells/ mm3 should be monitored in order to avoid treatment default and thereby prevent death. New studies should be conducted with a larger sample size and a longer follow-up time in PLHIV who initiated ART treatment early so as to support clinical decisions for a better understanding of immune behavior.